FDA's Drug Abuse Advisory Committee
This article was originally published in The Tan Sheet
Executive Summary
Will discuss "abuse liability assessment and related issues" regarding Kabi Pharmacia's NDA for a prescription nicotine nasal spray on the first day of an Aug. 1- 3 meeting. On Aug. 2, the committee will address issues related to nicotine and smoking, including the relationship between nicotine dose and addiction in smokers. The meeting will begin at 9 a.m. each day in the Plaza Ballroom of the Holiday Inn at 8777 Georgia Avenue, Silver Spring, Md